CSIMarket Company Name, Ticker, Industry, else..


Castle Biosciences Inc   (NASDAQ: CSTL)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Castle Biosciences Inc

CSTL's Fundamental analysis



Looking into Castle Biosciences Inc growth rates, revenue grew by 30.54 % in IV. Quarter 2024 from the same quarter a year ago. Ranking at No. 1327

Medical Laboratories industry recorded growth of revenues by 6.35 %

Castle Biosciences Inc realized net income compared to net loss a year ago in IV. Quarter 2024

• More on CSTL's Growth


Castle Biosciences Inc
current PE on trailing twelve month basis is above Medical Laboratories industry average.

Castle Biosciences Inc PEG ratio is at -0.27 Company is currently trading with Price to Cash flow multiple of 27.99 in trailing twelve-month period.
Company
34.09
PE TTM   
Industry
-0
PE TTM    
Company's Price to Sales ratio is at 1.76.
Medical Laboratories industry's Price to Sales ratio is at 2.2.


• More on CSTL's Valuation
 
 Total Debt (Millions $) 10
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 2,024,811
 Net Income/Employee (TTM) $ 242,738
 Receivable Turnover (TTM) 6.98
 Tangible Book Value (Per Share $) 11.88

Castle Biosciences Inc
current PE on trailing twelve month basis is above Medical Laboratories industry average.

Castle Biosciences Inc PEG ratio is at -0.27 Company is currently trading with Price to Cash flow multiple of 27.99 in trailing twelve-month period.
Company
34.09
PE TTM   
Industry
-0
PE TTM    
Company's Price to Sales ratio is at 1.76.
Medical Laboratories industry's Price to Sales ratio is at 2.2.

Castle Biosciences Inc Price to Book Ratio is at 1.28 lower than Industry Avg. of 149.13. and higher than S&P 500 Avg. of 0.01

• More on CSTL's Valuation

•  Market Capitalization (Millions $) 584
•  Shares Outstanding (Millions) 29
•  Employees 164
•  Revenues (TTM) (Millions $) 332
•  Net Income (TTM) (Millions $) 40
•  Cash Flow (TTM) (Millions $) 21
•  Capital Exp. (TTM) (Millions $) -28
•  Total Debt (Millions $) 10
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 2,024,811
•  Net Income/Employee(TTM) $ 242,738
•  Receivable Turnover Ratio (TTM) 6.98
•  Tangible Book Value (Per Share $) 11.88

•  Market Capitalization (Millions $) 584
•  Shares Outstanding (Millions) 29
•  Employees 164
•  Revenues (TTM) (Millions $) 332
•  Net Income (TTM) (Millions $) 40
•  Cash Flow (TTM) (Millions $) 21
•  Capital Exp. (TTM) (Millions $) -28


    CSTL's Profitability Comparisons
Castle Biosciences Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 4.69 % from 5.92 % in III. Quarter.

Castle Biosciences Inc net profit margin of 14.48 % is currently ranking no. 10 in Medical Laboratories industry, ranking no. 94 in Healthcare sector and number 1086 in S&P 500.


Profitability by Segment
Total 12.3 %



  Ratio
•   Capital Ratio (MRQ) 7.29
•  Total Debt to Equity (MRQ) 0.02
•  Tangible Leverage Ratio (MRQ) 0.22
•  Asset Turnover Ratio (TTM) 0.68
•  Inventory Turnover Ratio (TTM) 7.93



Castle Biosciences Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 4.69 % from 5.92 % in III. Quarter.

Castle Biosciences Inc net profit margin of 14.48 % is currently ranking no. 10 in Medical Laboratories industry, ranking no. 94 in Healthcare sector and number 1086 in S&P 500.

• More on CSTL's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com